Avid Bioservices Inc (CDMO)

[pphmtoolong]

Bulldog. Yes PPHM is a gamble, but comparing Cotara and to Bavi is accurate only in that they are both MABs. Obviously Cotara did not turn out to be what the then management thought it would be. The investors at that time were similarly wrong.

Noone cared that Cotara had some intriguing possibilities. The brain cancer market was too small and MABs carrying radiation was too difficult to work with based on the limited effectiveness.

We may be wrong about Bavi, but the underlying science of Bavi and vascular targeting seems much more main stream. This is supported by PPHM's ability to attract an impressive SAB.

Current management's focus of Bavi on HCV and very common cancers does evince an awareness of the need to monetize the investment.

All eyes on Florida and India. Soon we'll see if we are looking at something different this time. Be a bulldog for a few more months, and maybe you'll get a juicy bone to chew.

Paul